Key Highlights

  • Nine months of net losses reached USD 898.1 million at Mirum Pharmaceuticals (NASDAQ:MIRM), up from USD 17.6 million a year earlier, while unrestricted cash and investments rose to USD 500.5 million.
  • Zevra Therapeutics (NASDAQ:ZVRA) turned in third-quarter Net Income of USD 19.2 million, or USD 0.26 per diluted share, after a USD 0.5 million loss a year earlier.
  • Regulatory authorization covered 25 countries for Contineum Therapeutics (NASDAQ:CTNM), with more than 100 clinical sites open for its PROPEL-IPF study as of October 10, 2026.
  • A 68% jump in third-quarter sales, to USD 33.5 million, led Alamar Biosciences (NASDAQ:ALMR) to a 2026 Revenue outlook of USD 121 million to USD 123 million.

Mirum Pharmaceuticals (NASDAQ:MIRM): Cash Rises Despite Heavy Losses

Mirum Pharmaceuticals (NASDAQ:MIRM) submitted its Quarterly Report for the period ended September 30, 2026 on November 3, 2026. Losses for the nine months totaled USD 898.1 million, and the accumulated Deficit rose to USD 1.6 billion from USD 667.5 million on December 31, 2025. Only USD 40.8 million of that loss landed in the third quarter, which places most of the total earlier in 2026. The extract does not itemize the drivers, though it lists the January 2026 Bluejay Therapeutics acquisition, an April 2026 rights agreement with Incyte covering zilurgisertib, and a September 2026 in-license. Unrestricted cash, equivalents and investments came to USD 500.5 million, compared with USD 391.4 million at December 31, 2025. Four medicines are approved, and the FDA granted approval to zilurgisertib, marketed as Atebrioz, in September 2026. AZURE-4 results for the hepatitis D antibody brelovitug are slated for the fourth quarter of 2026. Mirum Pharmaceuticals (NASDAQ:MIRM) expects losses to continue and may turn to Equity offerings, Debt or licensing, while product revenue can swing with large periodic orders from Takeda and distributors. The extract contained no product sales figures, so revenue growth cannot be assessed.

Zevra Therapeutics (NASDAQ:ZVRA): Operating Gains Drive the Result

Marketing MIPLYFFA and OLPRUVA is the Business of Zevra Therapeutics (NASDAQ:ZVRA), whose quarterly report went out on November 3, 2026. Revenue reached USD 37.8 million, roughly 45% above USD 26.1 million a year earlier, a figure derived by simple arithmetic from the two reported amounts. Operating Income more than doubled, climbing to USD 11.6 million from USD 4.1 million. Operations did not account for all of the gain, because other income contained a USD 5.1 million non-cash gain tied to a Warrant and a contingent value right liability. Net income of USD 19.2 million therefore beats operating income by USD 7.6 million, primarily because of items outside operations. Interest expense fell to nil after the debt was repaid, leaving long-term debt at zero on September 30, 2026, versus USD 61.9 million at year-end. Nine-month net income of USD 65.9 million trailed USD 71.1 million a year earlier, since 2025 included a USD 148.3 million gain on a priority review voucher. The filing included financial statements but lacked management discussion, which leaves product-level detail out of reach for Zevra Therapeutics (NASDAQ:ZVRA).

Contineum Therapeutics (NASDAQ:CTNM): Trial Footprint Spans 25 Countries

Contineum Therapeutics (NASDAQ:CTNM) published its quarterly report on November 3, 2026, covering the period through September 30. It is a drug developer without any approved product for sale. Its flagship candidate, PIPE-791, is in PROPEL-IPF, a global Phase 2 study in idiopathic pulmonary fibrosis, where dosing started in the first quarter of 2026. By October 10, 2026, the study held regulatory authorization in 25 countries and more than 100 sites were open, a broad recruitment footprint that says nothing about efficacy yet. A Phase 1b study in chronic pain reached its safety goal, though pain improvements versus placebo were exploratory. PIPE-307, partnered with J&J, failed its efficacy endpoints in multiple sclerosis in November 2025, and J&J holds sole discretion over any further development. The company's filing says it depends heavily on PIPE-791. The extract contained no cash, loss or runway figures, leaving funding needs unassessed. Thin trading is a live risk for Contineum Therapeutics (NASDAQ:CTNM): a handful of trades can shift the price, spreads may be wide, and quoted moves can reverse.

Alamar Biosciences (NASDAQ:ALMR): Consumables Lead Sales Growth

Alamar Biosciences (NASDAQ:ALMR) released third-quarter 2026 results on November 3, 2026. Sales hit USD 33.5 million versus USD 19.9 million a year earlier, driven by consumables, which rose 79% to USD 17.8 million, and instruments, which rose 50% to USD 8.5 million. The firm makes precision proteomics tools that pick up low-concentration protein biomarkers in blood. Gross Margin widened to 61.5% from 59.7%, yet operating expenses jumped 81% to USD 35.8 million, pushing the net loss to USD 13.3 million from USD 8.0 million. Full-year guidance was raised to USD 121 million to USD 123 million. Working back from nine-month revenue gives a fourth-quarter estimate of roughly USD 32.0 million to USD 34.0 million, which is own arithmetic and sits near the third-quarter level. Cash and investments stood at USD 231.5 million with no term debt, compared with USD 9.8 million at the end of 2025, and biopharma customers made up the largest revenue share for the first time. Tod White is leaving the president role on December 31, 2026. Being a recently listed small company, Alamar Biosciences (NASDAQ:ALMR) may trade on thin volume, with spreads that can be wide and quoted prices that can reverse.

Where Things Stand

The filings do not itemize Mirum's loss, though its 2026 Acquisition and licensing activity points to heavy spending on new assets, while Zevra's profit is partly non-operating. Mirum Pharmaceuticals (NASDAQ:MIRM) still held USD 500.5 million of cash after that spending. Zevra Therapeutics (NASDAQ:ZVRA) earned USD 19.2 million, but about USD 7.6 million came from non-operating items, so the USD 11.6 million of operating income is the cleaner gauge. Contineum Therapeutics (NASDAQ:CTNM) brings in no revenue and hangs on one lead asset, and the extract gives no funding numbers. On growth, Alamar Biosciences (NASDAQ:ALMR) stands out with sales up 68%, although the revised outlook points to a fourth quarter roughly flat with the third. Watch the AZURE-4 results, J&J's decision on PIPE-307 and the Zevra sales trend, none of which guarantees a particular outcome.